Table 1.

Trials of anti-JAK2 efficacy and safety meeting inclusion criteria.

	Number of patients enrolled in each arm	Primary endpoint	Previous ruxolitinib exposure	Platelets count at baseline	Minimal treatment period	Results
COMFORT-1 [37]	Ruxolitinib (n = 155)	SVR	No	≥100.109/L	24 weeks	Ruxolitinib was superior to placebo for spleen response (p < 0.001).
	Placebo (n = 154)
COMFORT-2 [5]	Ruxolitinib (n = 146)	SVR	No	≥50.109/L	48 weeks, data available at 24 weeks	Ruxolitinib was superior to BAT for spleen response (p < 0.001).
	BAT (n = 73)
JAKARTA-1 [38]	Fedratinib 400 mg daily (n = 96)	SVR	No	≥50.109/L	24 weeks	Fedratinib (all arms) was superior to placebo for spleen response (p < 0.001).
	Fedratinib 500 mg daily (n = 97)
	Placebo (n = 96)
PERSIST-1 [39]	Pacritinib (n = 220)	SVR	No	Not specified	24 weeks	Pacritinib was superior to BAT including watchful waiting for spleen response (p = 0.0003).
	BAT excluding anti JAK (n = 107)
PERSIST-2 [40]	Pacritinib 400 mg once daily (n = 104 (75a))	SVR, total symptom score reduction	Previous ruxolitinib exposure or not	Must be <100.109/L	24 weeks	Pacritinib (all arms) was superior to BAT including ruxolitinib for spleen response (p = 0.001) and for symptom response (p = 0.08).
	Pacritinib 200 mg twice daily (n = 107 (74a))
	BAT (n = 100 (72a))
SIMPLIFY-1 [28]	Momelotinib (n = 215)	SVR	No	≥50.109/L	24 weeks	Momelotinib was noninferior to ruxolitinib for spleen response (p = 0.011) but not for symptom response (p = 0.98). Momelotinib treatment was associated with a reduced transfusion requirement (p < 0.019).
	Ruxolitinib (n = 217)
SIMPLIFY-2 [27]	Momelotinib (n = 104)	SVR	Yes, after ruxolitinib exposure	Not specified	24 weeks	Momelotinib was not superior to BAT for spleen response (p = 0.90) but was superior in symptom response (p = 0.0006).
	BAT (n = 52)

SVR spleen volume reduction, BAT best available therapy.

^aOnly patients who completed at least 22 weeks of follow-up after randomization and before clinical hold were taken into account.